Health Care·Biotechnology·$11.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.94 | N/A | +38.85% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.94 | N/A | +38.85% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They noted the importance of continued investment in research and development.
Management highlighted strong performance in key therapeutic areas.
They emphasized ongoing commitment to innovation and pipeline development.
Exelixis Inc reported better-than-expected earnings per share, which indicates strong operational performance. However, the stock fell by 2.21% following the earnings release, likely due to the lack of revenue details and forward guidance. Investors may be cautious given the absence of specific future targets, despite the positive EPS surprise.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UDR INC REIT
Feb 9, 2026